Innovative Eye Drop Shows Promise in Protecting Vision with Targeted Delivery of Compounds

A groundbreaking eyedrop formulation has demonstrated early success in delivering protective compounds directly to the retina, opening new possibilities for the treatment of severe vision impairment. Developed by researchers at RMIT University, this eye drop targets retinal diseases such as age-related macular degeneration (AMD), which severely damages the macula and can lead to blindness in millions worldwide.

The formulation utilizes advanced nanotechnology called cubosomes to carry and stabilize lutein, a potent antioxidant found in Gac fruit, and deliver it efficiently to the back of the eye—a region traditionally accessible only through invasive injections. In preclinical studies with mice, the eyedrop reached the retina and maintained the active compound’s stability for months at room temperature. Moreover, cell culture experiments showed that lutein delivered via this new method protected retinal cells from stress and damage associated with vision loss.

This innovative approach could significantly improve patient experience by reducing reliance on uncomfortable and frequent eye injections. Dr. Dao Nguyen, who co-led the research, emphasized that if further studies confirm the safety and effectiveness, this eyedrop could serve as a preventative treatment for early stages of age-related macular degeneration, potentially reducing the need for invasive procedures. However, she clarified that the eyedrops are not intended to replace injections but to complement existing therapies.

The delivery platform's versatility was highlighted by team leader Associate Professor Tien Huynh, indicating it could be adapted for various compounds. The research team also developed a patented nanocarrier system capable of protecting fragile ingredients and releasing them gradually inside the eye, overcoming longstanding challenges in ocular drug delivery.

Clinician-scientist Associate Professor Chi Luu from CERA noted the promising potential of this approach to revolutionize AMD treatment. Nonetheless, the current stage of research involves cell and animal models without yet demonstrating improved disease outcomes. Future steps include collaborations with clinical and industry partners to progress toward human trials.

The study, titled "Optimizing lutein formulations for targeted ocular drug delivery: in vitro and in vivo insights," is published in ACS Applied Materials & Interfaces. This research adds to growing evidence on the benefits of plant-derived compounds like lutein in eye health and highlights new avenues for non-invasive treatment options for retinal diseases.

source: https://medicalxpress.com/news/2025-09-experimental-eyedrop-formula-compounds-vision.html